Biosimilar policy is the perfect example of what happens when the industry does not deliver constructively, with the government forced into policy responses like the disastrous 2023 catch-up statutory price reductions.
The terrible events of 2023 were born of a decade-old policy failure
March 11, 2025 Latest NewsBioPharmaComment
Latest Video
New Stories
-
US childhood vaccine move away from combinations contrasts with Australia’s national schedule
August 12, 2026 - - Latest News -
A sage appointment that puts DBG Health another step closer to a serious understanding of decision-making
August 12, 2026 - - Latest News -
Former minister joins DBG Health board as company broadens healthcare ambition
August 12, 2026 - - Latest News -
How education exposes the moral and ethical limits of our health decision-making
August 11, 2026 - - Latest News -
Percheron turns to former Arovella chief Michael Baker for next phase of HMBD 002 development
August 10, 2026 - - Latest News -
Australian company points to encouraging survival signal in mesothelioma CAR-T study
August 10, 2026 - - Australian Biotech -
GBMA White Paper calls for reforms to strengthen supply chain resilience
August 10, 2026 - - Latest News

